ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]
Authors:
- D. R. MatthewsDMD. R. Matthews
- for the Position Statement Writing GroupFGfor the Position Statement Writing Group
- 2 August 2012
- journal article
- letter
- Published by Springer Nature in Diabetologia
- Vol. 55 (10) , 2856-2857
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- A critique of the 2012 ADA/EASD position statementDiabetologia, 2012
- To what extent is the new position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) ‘personalised’?Diabetologia, 2012
- Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitorsDiabetologia, 2012
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysisBMJ, 2012
- Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 DiabetesHormone and Metabolic Research, 2009